WVE - WaVe Life Sciences Ltd Stock Price, Fair Value and News

5.01USD-0.07 (-1.38%)Market Closed

Market Summary

USD5.01-0.07

Market Closed

-1.38%

WVE Stock Price

View Fullscreen

WVE RSI Chart

WVE Valuation

Market Cap

621.2M

Price/Earnings (Trailing)

-10.8

Price/Sales (Trailing)

5.48

EV/EBITDA

-7.91

Price/Free Cashflow

-30.23

WVE Price/Sales (Trailing)

WVE Profitability

EBT Margin

-51.36%

Return on Equity

-145.12%

Return on Assets

-20.92%

Free Cashflow Yield

-3.31%

WVE Fundamentals

WVE Revenue

Revenue (TTM)

113.3M

Rev. Growth (Yr)

2.2K%

Rev. Growth (Qtr)

-40.96%

WVE Earnings

Earnings (TTM)

-57.5M

Earnings Growth (Yr)

62.81%

Earnings Growth (Qtr)

-324.16%

Breaking Down WVE Revenue

Last 7 days

-3.4%

Last 30 days

-12.0%

Last 90 days

15.5%

Trailing 12 Months

26.4%

How does WVE drawdown profile look like?

WVE Financial Health

Current Ratio

1.26

WVE Investor Care

Shares Dilution (1Y)

24.65%

Diluted EPS (TTM)

-0.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.8M	36.6M	85.5M	113.3M
2022	42.7M	40.3M	4.2M	3.6M
2021	0	18.7M	52.1M	50.4M
2020	17.1M	12.5M	13.0M	20.1M
2019	16.0M	18.8M	17.2M	16.0M
2018	4.9M	8.7M	11.9M	14.4M
2017	1.9M	2.5M	3.5M	3.9M
2016	0	543.0K	809.0K	1.5M
2015	0	0	0	152.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of WaVe Life Sciences Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	moran kyle	sold	-96,421	6.169	-15,630	chief financial officer
Dec 11, 2023	ra capital management, l.p.	bought	5,000,000	5.00	1,000,000	-
Dec 07, 2023	gsk plc	bought	16,500,000	5.00	3,300,000	-
Aug 23, 2023	moran kyle	sold	-176,119	4.752	-37,062	chief financial officer
Feb 16, 2023	bolno paul	sold	-118,776	4.04	-29,400	president and ceo
Feb 16, 2023	vargeese chandra	sold	-41,303	4.03	-10,249	see remarks
Feb 16, 2023	francis chris	sold	-41,339	4.03	-10,258	see remarks
Feb 16, 2023	moran kyle	sold	-39,305	4.04	-9,729	chief financial officer
Jun 16, 2022	ra capital management, l.p.	bought	20,382,100	2.15	9,480,050	-

Which funds bought or sold WVE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-51.53	-11,000	15,000	-%
Apr 23, 2024	James J. Burns & Company, LLC	sold off	-100	-328,000	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-21,996	158,686	-%
Apr 11, 2024	Fortitude Family Office, LLC	sold off	-100	-323	-	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	383	383	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	45.00	45.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	10.98	-172,214	6,627,750	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	128	1,985,120	3,950,430	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-21,257	148,420	-%

Are Funds Buying or Selling WVE?

Are funds buying WVE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own WVE

No. of Funds

Unveiling WaVe Life Sciences Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	maverick capital ltd	6.9%	8,447,804	SC 13G/A
Feb 14, 2024	683 capital management, llc	4.7%	5,600,000	SC 13G/A
Feb 13, 2024	bb biotech ag	3.7%	4,494,458	SC 13G/A
Feb 12, 2024	m28 capital management lp	6.0%	7,373,413	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	5.03%	5,987,730	SC 13G/A
Feb 06, 2024	gsk plc	11.5%	13,983,761	SC 13G/A
Feb 14, 2023	683 capital management, llc	6.9%	6e+06	SC 13G/A
Feb 14, 2023	maverick capital ltd	8.2%	7,097,664	SC 13G/A
Feb 14, 2023	bb biotech ag	5.2%	4,494,458	SC 13G/A
Feb 10, 2023	m28 capital management lp	6.8%	5,903,405	SC 13G/A

Recent SEC filings of WaVe Life Sciences Ltd

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	4	Insider Trading

Peers (Alternatives to WaVe Life Sciences Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

WaVe Life Sciences Ltd News

Latest updates

WaVe Life Sciences Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-41.0%	29,056,000	49,214,000	22,106,000	12,929,000	1,239,000	285,000	375,000	1,750,000	1,765,000	36,423,000	2,776,000	9,439,000	3,450,000	3,027,000	4,161,000	2,400,000	2,929,000	7,628,000	3,026,000	3,620,000	4,493,000
Operating Expenses	6.6%	47,738,000	44,770,000	45,579,000	43,214,000	44,802,000	39,184,000	42,539,000	39,844,000	37,875,000	44,030,000	42,604,000	39,752,000	37,865,000	41,683,000	54,154,000	62,933,000	57,108,000	53,245,000	51,014,000	52,563,000	42,725,000
S&GA Expenses	4.1%	13,664,000	13,128,000	12,265,000	12,235,000	13,724,000	11,609,000	12,806,000	12,374,000	12,114,000	12,944,000	10,969,000	9,719,000	9,590,000	10,205,000	12,996,000	13,805,000	12,523,000	11,640,000	10,901,000	12,754,000	9,849,000
R&D Expenses	7.7%	34,074,000	31,642,000	33,314,000	30,979,000	31,078,000	27,575,000	29,733,000	27,470,000	25,761,000	31,086,000	31,635,000	30,033,000	28,275,000	31,478,000	41,158,000	49,128,000	44,585,000	41,605,000	40,113,000	39,809,000	32,876,000
EBITDA Margin	49.5%	-0.47	-0.93	-3.41	-9.74	-42.34	-35.02	-2.81	-2.59	-2.81	-3.06	-4.46	-	-	-	-	-	-	-	-	-	-
Income Taxes	100.0%	-	-677,000	-	-	681,000	-	-	-	-204,000	-	-	-841,000	-	-	-	-	-	-	-	-117,000	-
Earnings Before Taxes	-347.2%	-16,256,000	6,575,000	-21,104,000	-27,405,000	-43,028,000	-39,004,000	-41,296,000	-37,814,000	-34,989,000	-6,230,000	-38,766,000	-29,630,000	-33,100,000	-40,528,000	-47,493,000	-56,770,000	-50,726,000	-41,942,000	-44,200,000	-37,990,000	-37,631,000
EBT Margin	48.3%	-0.51	-0.99	-3.57	-10.17	-44.16	-36.67	-2.98	-2.76	-2.99	-3.28	-4.72	-	-	-	-	-	-	-	-	-	-
Net Income	-324.2%	-16,256,000	7,252,000	-21,104,000	-27,405,000	-43,709,000	-39,004,000	-41,296,000	-37,814,000	-34,785,000	-6,230,000	-38,766,000	-28,789,000	-33,100,000	-40,528,000	-47,493,000	-56,770,000	-50,726,000	-41,942,000	-44,200,000	-37,887,000	-37,631,000
Net Income Margin	48.9%	-0.51	-0.99	-3.59	-10.21	-44.35	-36.62	-2.98	-2.75	-2.98	-3.25	-4.69	-	-	-	-	-	-	-	-	-	-
Free Cashflow	3.1%	-33,595,000	-34,655,000	-37,329,000	85,033,000	-33,644,000	-26,103,000	-29,314,000	-40,081,000	-7,048,000	-28,282,000	-9,740,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	37.5%	275	200	230	267	146	182	213	167	207	201	206	243	279	310	204	239	284	347	386	431	296
Current Assets	48.4%	235	159	185	220	99.00	131	160	124	163	158	159	195	230	258	147	150	185	250	290	315	202
Cash Equivalents	43.2%	200	140	173	208	88.00	97.00	123	62.00	151	124	144	149	184	216	216	121	147	209	253	288	175
Net PPE	-5.0%	13.00	14.00	15.00	16.00	17.00	19.00	20.00	21.00	22.00	24.00	26.00	27.00	29.00	31.00	33.00	35.00	36.00	37.00	38.00	40.00	40.00
Liabilities	-2.2%	227	233	274	294	184	178	174	160	167	163	177	182	189	194	201	210	213	225	217	226	215
Current Liabilities	86.5%	186	100	140	133	72.00	64.00	64.00	58.00	64.00	32.00	47.00	49.00	121	110	110	119	118	133	124	132	130
Shareholder's Equity	-	40.00	-	-	-	-45.09	-	31.00	-	32.00	30.00	22.00	53.00	83.00	108	-	21.00	64.00	115	160	197	73.00
Retained Earnings	-1.6%	-1,024	-1,008	-1,015	-994	-967	-923	-884	-843	-805	-770	-764	-725	-683	-654	-621	-580	-533	-476	-425	-383	-339
Additional Paid-In Capital	1.9%	129	127	125	122	119	117	113	92.00	88.00	84.00	78.00	76.00	72.00	68.00	65.00	61.00	57.00	52.00	47.00	42.00	38.00
Accumulated Depreciation	2.7%	43.00	42.00	40.00	39.00	38.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	20.4%	119	99.00	99.00	98.00	87.00	74.00	64.00	61.00	60.00	51.00	49.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	259	-	-	-	205	-	-	-	270	-	-	-	267	-	-	-	631	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.5%	-33,239	-34,457	-37,257	85,522	-33,440	-25,646	-28,822	-39,873	-7,033	-28,184	-9,401	-44,375	-31,415	-20,172	-38,145	-26,250	-61,240	-43,681	-32,929	-50,381	-32,820
Share Based Compensation	3.0%	2,352	2,284	2,409	2,750	2,907	3,366	6,950	3,971	3,726	5,896	2,722	4,063	3,219	3,284	3,794	3,999	4,987	5,020	5,157	4,345	4,011
Cashflow From Investing	-79.8%	-356	-198	-72.00	-489	24,840	-501	24,614	-50,208	-15.00	-98.00	-339	-108	-557	-65.00	-136	-580	-1,346	-465	-1,599	-508	-3,463
Cashflow From Financing	5526.5%	93,962	1,670	1,849	35,053	55.00	17.00	65,800	1,316	33,793	8,349	5,045	8,641	19.00	142,523	11,382	614	757	253	-157	163,546	646

WVE Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 113,305	$ 3,649
Operating expenses:
Research and development	130,009	115,856
General and administrative	51,292	50,513
Total operating expenses	181,301	166,369
Loss from operations	(67,996)	(162,720)
Other income, net:
Dividend income and interest income, net	7,928	1,571
Other income (expense), net	1,878	7
Total other income, net	9,806	1,578
Loss before income taxes	(58,190)	(161,142)
Income tax benefit (provision)	677	(681)
Net loss	$ (57,513)	$ (161,823)
Net loss per share attributable to ordinary shareholders basic	$ (0.54)	$ (2.05)
Net loss per share attributable to ordinary shareholders diluted	$ (0.54)	$ (2.05)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic.	106,097,268	78,855,810
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted	106,097,268	78,855,810
Other comprehensive loss:
Net Income (Loss)	$ (57,513)	$ (161,823)
Foreign currency translation	(95)	(210)
Comprehensive loss	$ (57,608)	$ (162,033)

WVE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 200,351	$ 88,497
Accounts receivable	21,086
Prepaid expenses	9,912	7,932
Other current assets	4,024	2,108
Total current assets	235,373	98,537
Long-term assets:
Property and equipment, net of accumulated depreciation of $42,709 and $37,846 as of December 31, 2023 and 2022, respectively	13,084	17,284
Operating lease right-of-use assets	22,637	26,843
Restricted cash	3,699	3,660
Other assets	156	62
Total long-term assets	39,576	47,849
Total assets	274,949	146,386
Current liabilities:
Accounts payable	12,839	16,915
Accrued expenses and other current liabilities	16,828	17,552
Current portion of deferred revenue	150,059	31,558
Current portion of operating lease liability	6,714	5,496
Total current liabilities	186,440	71,521
Long-term liabilities:
Deferred revenue, net of current portion	15,601	79,774
Operating lease liability, net of current portion	25,404	32,118
Other liabilities		190
Total long-term liabilities	41,005	112,082
Total liabilities	227,445	183,603
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at December 31, 2023 and 2022	7,874	7,874
Shareholders' equity (deficit):
Ordinary shares, no par value; 119,162,234 and 86,924,643 shares issued and outstanding at December 31, 2023 and 2022, respectively	935,367	802,833
Additional paid-in capital	129,237	119,442
Accumulated other comprehensive loss	(124)	(29)
Accumulated deficit	(1,024,850)	(967,337)
Total shareholders' equity (deficit)	39,630	(45,091)
Total liabilities, Series A preferred shares and shareholders' equity (deficit)	$ 274,949	$ 146,386

About WaVe Life Sciences Ltd

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

CEO	Dr. Paul B. Bolno M.B.A., M.D., MBA
WEBSITE	wavelifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	250

WaVe Life Sciences Ltd Frequently Asked Questions

What is the ticker symbol for WaVe Life Sciences Ltd? What does WVE stand for in stocks?

WVE is the stock ticker symbol of WaVe Life Sciences Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of WaVe Life Sciences Ltd (WVE)?

As of Tue Apr 23 2024, market cap of WaVe Life Sciences Ltd is 621.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WVE stock?

You can check WVE's fair value in chart for subscribers.

What is the fair value of WVE stock?

You can check WVE's fair value in chart for subscribers. The fair value of WaVe Life Sciences Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of WaVe Life Sciences Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WVE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is WaVe Life Sciences Ltd a good stock to buy?

The fair value guage provides a quick view whether WVE is over valued or under valued. Whether WaVe Life Sciences Ltd is cheap or expensive depends on the assumptions which impact WaVe Life Sciences Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WVE.

What is WaVe Life Sciences Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, WVE's PE ratio (Price to Earnings) is -10.8 and Price to Sales (PS) ratio is 5.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WVE PE ratio will change depending on the future growth rate expectations of investors.